Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
Healthcare
$3.28 +0.00%
+$0.00 today
- Market cap
- $571.17M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
52W Low $0.91High $3.22
Volume 0.23M
Average 0.16M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$7.37M
FY 2025 · Annual
Investing Cash Flow
-$107,000.00
FY 2025 · Annual
Financing Cash Flow
$13.71M
FY 2025 · Annual
+206.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| Deferred Income Tax | (217K) | 174K | 29K | 14K | 0 |
| Stock-Based Compensation | 1.86M | 2.25M | 1.69M | 2.56M | 2.75M |
| Change in Working Capital | 1.41M | (1.84M) | (195K) | 112K | 1.26M |
| Accounts Receivables | 72K | (63K) | 246K | (126K) | 126K |
| Inventory | (72K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 74K | (149K) | 66K | 49K | 316K |
| Other Working Capital | 1.34M | (1.62M) | (507K) | 189K | 815K |
| Other Non-Cash Items | 18K | (78K) | 1.69M | (5K) | 32K |
| Operating Cash Flow | (9.06M) | (12.5M) | (7.31M) | (6.82M) | (7.37M) |
| Capital Expenditures | (17K) | (47K) | (17K) | (3K) | (107K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (55K) | 0 | 0 | 0 |
| Investing Cash Flow | (17K) | (102K) | (17K) | (3K) | (107K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 21.81M | 13K | 6.62M | 3.96M | 13.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.58M | 0 | (580K) | 516K | 0 |
| Financing Cash Flow | 25.38M | 13K | 6.04M | 4.48M | 13.71M |
| Effect of Forex Changes | 0 | 5K | 0 | 0 | (10K) |
| Net Change in Cash | 16.3M | (12.58M) | (1.29M) | (2.35M) | 6.23M |
| Free Cash Flow | (9.08M) | (12.55M) | (7.33M) | (6.82M) | (7.48M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$11.4M
+ D&A$30.0K
+ Stock-Based Comp$2.8M
+ Deferred Tax$0
+ Working Capital$1.3M
+ Other Non-Cash$32.0K
= Operating Cash Flow-$7.4M
- Capex-$107.0K
= Free Cash Flow-$7.5M
Analysis
FY2025 free cash flow is -$7.5M. FCF conversion is 65.4% of net income. Operating cash flow was -$7.4M, with capex of -$107.0K. The largest bridge item is Stock-Based Comp at $2.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 8-K | Current report | Oct 27, 2026 |
Does ENTX generate free cash flow?
Entera Bio Ltd. (ENTX) generated -$7.48M of free cash flow in fiscal 2025.
How much operating cash flow does ENTX produce?
Operating cash flow was -$7.37M, before capital expenditures of $107,000.00.
Continue the stock analysis
Jump to another research area for this company.